Exact Sciences schedules annual meeting, second quarter 2020 earnings call

Rhea-AI Summary

Exact Sciences Corp. (Nasdaq: EXAS) announced its virtual annual stockholders meeting and second quarter 2020 earnings call. The meeting is scheduled for July 23, 2020, at 11 a.m. ET. The second quarter earnings release will occur on July 30, 2020, after U.S. market close, followed by a conference call at 5 p.m. ET. Investors can access the live webcasts and archives via the company's website. Exact Sciences focuses on cancer screening and diagnostics, with products like Cologuard and Oncotype DX.

Positive

• Exact Sciences continues to invest in its product pipeline, aiming to tackle deadly cancers.
• The scheduled earnings call suggests ongoing communication and transparency with investors.

Negative

• None.

MADISON, Wis., July 8, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company has scheduled its virtual annual stockholders meeting and second quarter 2020 earnings call.

Annual Meeting of Stockholders Webcast Details

Date:	Thursday, July 23, 2020
Time:	11 a.m. ET, 10 a.m. CT
Webcast:	The live webcast can be accessed at www.exactsciences.com

The company plans to release its second quarter 2020 financial results after the close of the U.S. financial markets on July 30, 2020. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Second Quarter 2020 Webcast & Conference Call Details

Date:	Thursday, July 30, 2020
Time:	5 p.m. ET, 4 p.m. CT
Webcast:	The live webcast can be accessed at www.exactsciences.com
Telephone:	Domestic callers, dial 833-235-7650  International callers, dial +1 647-689-4171 Access code for both domestic and international callers: 8183605

An archive of both webcasts will be available at www.exactsciences.com. A telephone replay of the second quarter 2020 conference call will be available by calling 800-585-8367 domestically or 416-621-4642 internationally. The access code for the replay of the call is 8183605. The webcast, conference call and replay are open to all interested parties.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections.  Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms.  All statements other than statements of historical facts included in this news release regarding our strategies, prospects, expectations, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, and the anticipated results of our product development efforts.  Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the success of our efforts to facilitate patient access to Cologuard via telehealth; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; the amount and nature of competition for our products and services; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the effects of changes in pricing, coverage and reimbursement for our products and services, including without limitation as a result of the Protecting Access to Medicare Act of 2014; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Society of Clinical Oncology, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services and assess potential market opportunities; our ability to effectively enter into and utilize strategic partnerships, such as through our Promotion Agreement with Pfizer, Inc., and acquisitions; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; our ability to manage an international business and our expectations regarding our international expansion and opportunities; the potential effects of foreign currency exchange rate fluctuations and our efforts to hedge such effects; the possibility that the anticipated benefits from our combination with Genomic Health cannot be realized in full or at all or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Genomic Health's operations will be greater than expected and the possibility of disruptions to our business during integration efforts and strain on management time and resources; the outcome of any litigation, government investigations, enforcement actions or other legal proceedings; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact:
Megan Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815

View original content to download multimedia:http://www.prnewswire.com/news-releases/exact-sciences-schedules-annual-meeting-second-quarter-2020-earnings-call-301089745.html

SOURCE EXACT SCIENCES CORP

FAQ

When is Exact Sciences' second quarter 2020 earnings call?

The earnings call is scheduled for July 30, 2020, at 5 p.m. ET.

What are the details of Exact Sciences' annual stockholders meeting?

The virtual annual stockholders meeting will take place on July 23, 2020, at 11 a.m. ET.

How can I access the webcasts for Exact Sciences' meetings?

Webcasts can be accessed via Exact Sciences' website at www.exactsciences.com.

What is the main focus of Exact Sciences?

Exact Sciences specializes in cancer screening and diagnostic tests, including Cologuard.